Wegovy is the first-to-market in a new class of highly effective weight-loss drugs.
The self-injection drug has transformed the fortunes of Novo, whose shares have surged about 165% since Wegovy's U.S. launch two years ago.
The lion's share may be claimed by frontrunners Novo and its U.S. rival Eli Lilly and Co (LLY.N).
Last month, Novo launched Wegovy in Germany, its first big European market.
Reporting by Maggie Fick and Jacob Gronholt-Pedersen Editing by Josephine Mason and Mark PotterOur Standards: The Thomson Reuters Trust Principles.
Persons:
Novo Nordisk Lars Fruergaard Jorgensen, LUDOVIC MARIN, Lars Fruergaard Jorgensen's, Jorgensen, Eli Lilly, Wegovy, Novo, Maggie Fick, Jacob Gronholt, Pedersen, Josephine Mason, Mark Potter
Organizations:
Novo Nordisk, Chateau, BMI, Reuters, frontrunners Novo, Pfizer, Thomson
Locations:
Versailles, Paris, COPENHAGEN, Europe, Danish, United States, Denmark, Norway, Brussels, Wegovy, Germany